The use of embryonic stem cells for regulatory developmental toxicity testing in vitro -: The current status of test development

被引:63
作者
Bremer, S [1 ]
Hartung, T [1 ]
机构
[1] Commiss European Communities, Inst Hlth & Consumer Protect, Joint Res Ctr, ECVAM, I-21020 Ispra, VA, Italy
关键词
embryonic stem cells; developmental toxicity; alternative method; chemical policy; test strategy;
D O I
10.2174/1381612043383700
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The future chemical policy of the European Union as well as the 7th amendment of the cosmetic directive is calling for the development of alternative tests to animal experimentation for toxicological safety testing. In the field of embryotoxicity one or the most promising in vitro models are based on embryonic stein cells. The embryonic stem cell test has already been validated in comparison to in vivo results in an international blind collaboration study. The presented review is discussing the use, limitations and further needs for the test in order to be fully suitable for regulatory acceptance. In this context, it is summarized which requirements for an in vitro embryotoxicity test have to be fulfilled for regulatory toxicity testing. In addition, an overview about the Current status of test development of other embryonic stem cell tests is presented. Several workshops have reviewed the progress of in vitro tests for developmental toxicity testing. A general consensus Of these workshops has been that one single test will not be sufficient to cover all manifestations of developmental toxicity. The establishment of a test battery for developmental toxicity is required. This will be even more challenging since the principles of a composing test strategy and its validation have not been defined yet. Finally, the unique possibility of combining the human embryonic stem cell technology and the microarray techniques might lead to a deeper understanding of the toxicological mechanisms of human developmental toxicants.
引用
收藏
页码:2733 / 2747
页数:15
相关论文
共 106 条
  • [1] Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis an inflammatory diseases
    Ahn, HS
    Chackalamannil, S
    Boykow, G
    Graziano, MP
    Foster, C
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (28) : 2349 - 2365
  • [2] Temporospatial relationships between macroglia and microglia during in vitro differentiation of murine stem cells
    Angelov, DN
    Arnhold, S
    Andressen, C
    Grabsch, H
    Puschmann, M
    Hescheler, J
    Addicks, K
    [J]. DEVELOPMENTAL NEUROSCIENCE, 1998, 20 (01) : 42 - 51
  • [3] [Anonymous], 2001, White Paper: Strategyfor afuture Chemicals
  • [4] [Anonymous], 2000, ETHICAL ASPECTS HUMA
  • [5] [Anonymous], 2001, OECD GUIDELINES TEST
  • [6] mTert expression correlates with telomerase activity during the differentiation of murine embryonic stem cells
    Armstrong, L
    Lako, M
    Lincoln, J
    Cairns, PM
    Hole, N
    [J]. MECHANISMS OF DEVELOPMENT, 2000, 97 (1-2) : 109 - 116
  • [7] IMMUNOCHEMICAL ANALYSIS OF MYOSIN HEAVY-CHAIN DURING AVIAN MYOGENESIS INVIVO AND INVITRO
    BADER, D
    MASAKI, T
    FISCHMAN, DA
    [J]. JOURNAL OF CELL BIOLOGY, 1982, 95 (03) : 763 - 770
  • [8] Differentiation of embryonal stem cells into keratinocytes: Comparison of wild-type and beta(1) integrin-deficient cells
    Bagutti, C
    Wobus, AM
    Fassler, R
    Watt, FM
    [J]. DEVELOPMENTAL BIOLOGY, 1996, 179 (01) : 184 - 196
  • [9] Embryonic stem cells and in vitro muscle development
    Baker, RK
    Lyons, GE
    [J]. CURRENT TOPICS IN DEVELOPMENTAL BIOLOGY, VOL 33, 1996, 33 : 263 - 279
  • [10] The relative semi-quantification of mRNA expression as a useful toxicological endpoint for the identification of embryotoxic/teratogenic substances
    Bigot, K
    De Lange, J
    Archer, G
    Clothier, R
    Bremer, S
    [J]. TOXICOLOGY IN VITRO, 1999, 13 (4-5) : 619 - 623